For research use only
| Cat No. | ABC-SC0096 |
| Product Type | Human Cancer Stem Cells |
| Cell Type | Stem Cell |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Head And Neck |
| Disease | Head and Neck Cancer |
| Storage | Liquid Nitrogen |
Human Head and Neck Cancer Stem Cell; Frozen Vial and Plated cells are available.
HighQC™ Human Head and Neck Cancer Stem Cells (HNSCC CSCs) are enriched subpopulations derived from primary head and neck squamous cell carcinoma (HNSCC) tissue. These cells exhibit stem-like characteristics, including self-renewal, tumorigenicity, and resistance to chemotherapy. Morphologically, they display spheroid or loosely adherent phenotypes in serum-free stem cell media. HNCSCs are characterized by elevated expression of stemness and tumor-initiating markers such as CD44, CD133, SSEA3/4, Oct4, as confirmed by flow cytometry and qRT-PCR. The cells are capable of forming tumorspheres and initiating xenograft tumors in immunocompromised mice, mimicking clinical tumor behavior. Each lot undergoes rigorous screening and isolation procedures, and is rigorously tested to ensure it is free of contamination from HIV-1, HBV, HCV, syphilis, mycoplasma, fungi, yeast, and bacteria.
| Product Code | HighQC™ Human Head And Neck Cancer Stem Cell, Human HNC SC, hHNCSC, Human Head & Neck CSC |
| Species | Human |
| Cat.No | ABC-SC0096 |
| Product Category | Stem Cells |
| Size/Quantity | 1 vial |
| Cell Type | Stem Cell |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Head And Neck |
| Disease | Head and Neck Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Cancer Stem Cells |
HighQC™ Human Head and Neck Cancer Stem Cells provide a powerful tool for studying tumor initiation, therapy resistance, and metastasis in HNSCC. They are suitable for screening anti-cancer drugs targeting cancer stemness, identifying biomarkers predictive of recurrence, and modeling epithelial-to-mesenchymal transition (EMT) and immune evasion. These cells support both 2D and 3D tumor modeling systems, including patient-derived xenografts and organoid formation, enabling translational cancer research and personalized therapy development.
When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).